Clarus Therapeutics Holdings, Inc.
CRXTDelisted Sep 14, 2022- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001817944
Clarus Therapeutics Holdings, Inc. was delisted on Sep 14, 2022; its insiders filed their last Form 4 on Jun 9, 2022; 25 institutions reported holding it in 13F filings for Q2 2022, worth $1.82M in total; no superinvestor held it.
13F holders, Q4 2021
Institutional positions in Clarus Therapeutics Holdings, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 12
- 0 vs. Q3 2021
- Shares held
- 4.30M
- +2.04M (+90.3%) vs. Q3 2021
- Total value
- $10.5M
- −$1.59M (−13.2%) vs. Q3 2021
- New holders
- 7
- 2 more added
- Sold out
- 7
- 1 more reduced
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CRXT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 0 | $0 |
| Q1 2026 | 0 | $0 |
| Q4 2025 | 1 | $0 |
| Q3 2025 | 0 | $0 |
| Q2 2025 | 0 | $0 |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 2 | $5.00K |
| Q2 2022 | 25 | $1.82M |
| Q1 2022 | 13 | $3.73M |
| Q4 2021 | 12 | $10.5M |
| Q3 2021 | 12 | $12.1M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Clarus Therapeutics Holdings, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bracebridge Capital, LLC | 2,002,495 | $4.87M | 1.47% | 00.0% | Unchanged |
| Armistice Capital, LLC | 1,929,876 | $4.69M | 0.11% | +1,929,876 | New |
| Vanguard Group Inc | 166,600 | $405.0K | 0.00% | +166,600 | New |
| Powell Investment Advisors, LLC | 64,000 | $156.0K | 0.09% | +21,000+48.8% | Added |
| UBS Group AG | 45,631 | $111.0K | 0.00% | +6,977+18.0% | Added |
| Verition Fund Management LLC | 30,000 | $73.0K | 0.00% | 00.0% | Unchanged |
| Schonfeld Strategic Advisors LLC | 20,800 | $51.0K | 0.00% | +20,800 | New |
| Tudor Investment Corp Et Al | 18,148 | $44.0K | 0.00% | +18,148 | New |
| Tower Research Capital LLC (TRC) | 12,923 | $31.0K | 0.00% | −30,422−70.2% | Reduced |
| Citadel Advisors LLC | 12,597 | $31.0K | 0.00% | +12,597 | New |
| Wells Fargo & Company | 25 | $0 | 0.00% | +25 | New |
| Morgan Stanley | 2 | $0 | 0.00% | +2 | New |
| Telemetry Investments, L.L.C. | 0 | $0 | 0.00% | −45,000−100.0% | Sold out |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −22,543−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −17,704−100.0% | Sold out |
| Cowen and Company, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −7,846−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −200−100.0% | Sold out |